AusperBio Advances AHB-137 to Phase III Clinical Trials
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. collectively referred to as AusperBio, has made significant strides in the fight against chronic hepatitis B (CHB). The company recently announced that it received clearance from the China Center for Drug Evaluation (CDE) to initiate a Phase III clinical trial for AHB-137, its leading candidate designed to offer targeted treatment solutions for CHB.
Details of the Phase III Trial
The Phase III clinical trial is structured as a randomized, double-blind, multicenter study aimed at evaluating the efficacy and safety of a 24-week treatment regimen involving AHB-137 (300 mg). This specific trial will focus on patients who are HBeAg-negative and are already undergoing stable nucleos(t)ide analogue therapy.
Understanding Chronic Hepatitis B
Chronic Hepatitis B is a critical liver disease that affects an estimated 290 million individuals worldwide, with a significant portion of these patients based in Asia. This viral infection can lead to severe complications such as cirrhosis and liver cancer, which highlights the urgent need for effective treatments. Current available therapies typically manage the virus, but true functional cures remain elusive for most patients.
Significance of AHB-137
AHB-137 represents a novel approach in treating chronic hepatitis B, classified as an antisense oligonucleotide. This innovative treatment has garnered significant attention, having received Breakthrough Therapy Designation from the China CDE, an acknowledgment of its potential to dramatically enhance treatment outcomes against conventional methods. Recent presentations of data derived from earlier Phase trials have underscored AHB-137's promising efficacy and safety, affirming optimistic projections for its future applications.
CEO Insights on the Advancement
Dr. Guofeng Cheng, Co-founder and CEO of AusperBio, expressed enthusiasm regarding the Phase III progression, stating, "We are thrilled to receive clearance from the China CDE to launch Phase III development of AHB-137. This approval, reflecting our efforts to enhance treatment for chronic hepatitis B, is a substantial milestone in our journey." His statement emphasizes the collective effort of the team, investigators, and patients in reaching this significant achievement.
Looking Toward the Future of CHB Treatment
The commitment from AusperBio to foster advancements in therapeutics for chronic hepatitis B is unwavering. The company aims to initiate the Phase III trial promptly, aspiring to provide a groundbreaking treatment option that could change the lives of countless CHB patients. This trial approval is pivotal in progressing toward their goal of science-based, patient-focused solutions.
About AHB-137 and Its Technology
AHB-137 is not just another drug in development; it’s a product of advanced research utilizing AusperBio's proprietary Med-Oligo™ ASO technology. Designed to trigger a biological response within the complex pathways involved in hepatitis B, the ASO has already undergone a successful global Phase 1 trial and is making headway through several Phase 2 studies.
About AusperBio
AusperBio is a biopharmaceutical company dedicated to the fight against chronic hepatitis B infection. By harnessing the power of oligonucleotide therapies and modern delivery mechanisms, AusperBio aims to reshape therapeutic strategies in biomedicine. Their innovative Med-Oligo™ ASO platform enhances the functionality of current ASO therapeutics and facilitates treatment options for a wide range of diseases.
Frequently Asked Questions
What is the goal of the Phase III trial for AHB-137?
The Phase III trial aims to evaluate the efficacy and safety of AHB-137 in chronic hepatitis B patients, seeking to confirm its potential as a functional cure.
How does AHB-137 differ from current treatments?
AHB-137 is designed as an antisense oligonucleotide with a novel mechanism that seeks to achieve a functional cure, rather than just managing symptoms.
Who is involved in the clinical trials?
The trials involve a network of investigators, clinical teams, and participants who are committed to advancing treatment for chronic hepatitis B.
What recognition has AHB-137 received?
AHB-137 received Breakthrough Therapy Designation from the China CDE, indicating its potential impact on treatment outcomes for chronic hepatitis B.
What is AusperBio's vision for the future?
AusperBio aims to develop effective treatments that offer functional cures for chronic hepatitis B, changing the landscape of care for millions of patients worldwide.
